📅 Fiers de participer au 24ème congrès annuel de la SFGM-TC 2025, à Genève !
🔬 Nous présenterons à nouveau des données cliniques issues du programme EAP sous la forme d’une communication orale, ainsi que deux posters dédiés à MaaT013 et MaaT033.

🔎 Toutes les informations dans le visuel ci-dessous 👇

📰 [#PressRelease] - MaaT Pharma announces the successful completion of its Global Offering of €9.1 million
👉 www.maatpharma.com/november-14-...

📰 [#PressRelease] – MaaT Pharma Launches a Capital Increase of Approximately €9 Million

👉 Read the press release: www.maatpharma.com/november-13-...

📰 MaaT Pharma To Present Updated Preclinical Data at SITC (@sitcancer.bsky.social) 2025.
We’re excited to share promising updated results for MaaT034 showing immune activation and anti-tumor activity in germ-free models.

👉 Full press release: www.maatpharma.com/november-5-2...

📰 [PressRelease] – We’re thrilled to announce that our Phase 3 results evaluating Xervyteg® (MaaT013) in acute Graft-versus-Host Disease (#aGvHD) have been selected for oral presentation at ASH Congress 2025.
👉 Read the full press release: www.maatpharma.com/november-3-2...

📄 [#PressRelease] - MaaT Pharma Reports Financial Results for the Third Quarter 2025 and Provides Financing Update

📍Next stops: SITC, SFGM-TC, Investir Day, ASH – see you there!

👉 Read the full press release: www.maatpharma.com/november-4-2...

📰 [PressRelease] - We’re proud to share that the DSMB has issued a positive recommendation following the second safety interim analysis of our Phase 2b PHOEBUS trial evaluating MaaT033 in patients receiving allo-HSCT.

👉 Read the full press release here: www.maatpharma.com/october-7-20...

📄 [Press release] - MaaT Pharma Publishes its Half Year 2025 Financial Results and Provides a Business Update

👉 Read the full press release for more information: www.maatpharma.com/september-17...

#BusinessUpdate #FinancialResults #Oncology #Microbiome #aGvHD #Hematology